Low-dose blinatumomab in multidrug-resistant RA 15 pts 96h cycles CD3×CD19 T-cell engager DAS28-CRP: 4.8 → 2.4 3 mo ACR20 100% ACR50 73% ACR70 53% DAS28 remission 33% But... only transient efficacy with 93% relapse after stopping treatment Authors highlight response to https://t.co/GCS6774tJt